Home/Filings/4/0001104659-22-123686
4//SEC Filing

Dahms Bradford D. 4

Accession 0001104659-22-123686

CIK 0001745020other

Filed

Nov 30, 7:00 PM ET

Accepted

Dec 1, 4:35 PM ET

Size

5.3 KB

Accession

0001104659-22-123686

Insider Transaction Report

Form 4
Period: 2022-11-30
Dahms Bradford D.
Chief Financial Officer
Transactions
  • Purchase

    Common Stock

    2022-11-30$6.66/sh+1,502.189$10,0006,142.225 total
Footnotes (2)
  • [F1]The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transaction at prices ranging from $6.56 to $6.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
  • [F2]Includes 1,162 shares and 1,508 shares previously purchased under the Issuer's 2021 Employee Stock Purchase Plan on May 13, 2022 and November 14, 2022, respectively.

Issuer

Theseus Pharmaceuticals, Inc.

CIK 0001745020

Entity typeother

Related Parties

1
  • filerCIK 0001787307

Filing Metadata

Form type
4
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 4:35 PM ET
Size
5.3 KB